Patents by Inventor Paul M. Keller
Paul M. Keller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110052611Abstract: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A? in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A?, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A?. In another aspect, the immunogenic fragment of A? is capable of elevating plasma A? levels. The immunogenic fragments comprise linear or multivalent peptides of A?. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.Type: ApplicationFiled: November 8, 2010Publication date: March 3, 2011Inventors: VICTOR M. GARSKY, JOSEPH G. JOYCE, PAUL M. KELLER, GENE KINNEY, XIAOPING LIANG, JOHN W. SHIVER
-
Patent number: 7850973Abstract: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A? in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A?, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A?. In another aspect, the immunogenic fragment of A? is capable of elevating plasma A? levels. The immunogenic fragments comprise linear or multivalent peptides of A?. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.Type: GrantFiled: May 1, 2006Date of Patent: December 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Victor M. Garsky, Joseph G. Joyce, Paul M. Keller, Gene Kinney, Xiaoping Liang, John W. Shiver
-
Publication number: 20090098155Abstract: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A? in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of A?, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to A?. In another aspect, the immunogenic fragment of A? is capable of elevating plasma A? levels. The immunogenic fragments comprise linear or multivalent peptides of A?. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.Type: ApplicationFiled: May 1, 2006Publication date: April 16, 2009Inventors: Victor M. Garsky, Joseph G. Joyce, Paul M. Keller, Gene Kinney, Xiaoping Liang, John W. Shiver
-
Patent number: 7157443Abstract: A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,?-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from Staphylococcus aureus. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.Type: GrantFiled: December 6, 2002Date of Patent: January 2, 2007Assignee: Merck & Co., Inc.Inventors: Joseph G. Joyce, James C. Cook, III, Chitrananda Abeygunawardana, Karen M. Grimm, Craig T. Przysiecki, Robert W. Hepler, Charlotte C. Ip, Keith Roper, Qiuwei Xu, Kathrin U. Jansen, Paul M. Keller, Leslie D. Cope
-
Patent number: 7048926Abstract: The invention provides methods for using agonists and antagonists of FabK polypeptides, particularly to modulate the metabolism of bacteria or to treat bacterial infection.Type: GrantFiled: April 4, 2003Date of Patent: May 23, 2006Assignee: Affinium Pharmaceuticals, Inc.Inventors: Martin Brandt, Walter E. DeWolf, Jr., Paul M. Keller, Arunbhai H. Patel, David J. Payne, Shannon L. Reed, Mark A. Seefeld, David G. Tew, Nicola G. Wallis, Joshua M. West
-
Publication number: 20040259838Abstract: A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,&bgr;-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from Staphylococcus aureus. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.Type: ApplicationFiled: June 9, 2004Publication date: December 23, 2004Inventors: Joseph G. Joyce, James C. Cook III, Chitrananda Abeygunawardana, Karen M. Grimm, Craig T. Przysiecki, Robert W. Hepler, Charlotte C. Ip, Donald Keith Roper, Qi Wei Xu, Kathrin U. Jansen, Paul M. Keller, Leslie D. Cope
-
Publication number: 20040053814Abstract: The invention provides methods for using agonists and antagonists of FabK polypeptides, particularly to modulate the metabolism of bacteria or to treat bacterial infection.Type: ApplicationFiled: April 4, 2003Publication date: March 18, 2004Inventors: Martin Brandt, Walter E. Dewolf, Paul M. Keller, Arunbhai H. Patel, David J. Payne, Shannon L. Reed, Mark A. Seefeld, David G. Tew, Nicola G. Wallis, Joshua M. West
-
Publication number: 20030224011Abstract: The present invention features HCV conjugates able to induce an immune response recognizing different strains and variants of HCV. The conjugates contain a polypeptide or protein complex carrier and one or more HCV mimotopes. Preferred HCV mimotopes provide antigens able to generate antibodies recognizing the hypervariable region of the HCV E2 protein.Type: ApplicationFiled: February 11, 2003Publication date: December 4, 2003Inventors: Anthony J. Conley, Philip M. McKenna, Craig T. Przysiecki, Paul M. Keller
-
Patent number: 6372425Abstract: A process of purifying target molecules is described that involves the selection of ligands based on identifying, in real time, association and dissociation constants with a given target molecule; using this information to select at least one ligand that exhibit predetermined association and dissociation constants with a given target molecule; anchoring a quantity of ligand to an activated solid support; contacting a quantity of target molecules with the anchored ligand(s); removing low affinity target molecules from anchored ligand and eluting particularly pure target molecules.Type: GrantFiled: August 21, 1998Date of Patent: April 16, 2002Assignee: Merck & Co., Inc.Inventors: Beth Arnold, Paul M. Keller, Anthony J. Conley, Alan R. Shaw, Jwu-Sheng Tung
-
Patent number: 5763574Abstract: Immunological conjugates of HIV-specific selected principal neutralization epitopes are prepared. These epitopes bind 19b, a broadly neutralizing human monoclonal antibody specific for the HIV gp120. The epitopes are identified from oligopeptide epitope libraries. The conjugates are useful for vaccination against AIDS or ARC, as well as in the production of other HIV-specific broadly neutralizing antibodies for passive immunity against AIDS or ARC.Type: GrantFiled: April 4, 1996Date of Patent: June 9, 1998Assignee: Merck & Co., Inc.Inventors: Anthony J. Conley, Beth A. Arnold, Lynn J. Boots, Paul M. Keller
-
Patent number: 5340726Abstract: A protein which inhibits collagen-stimulated platelet aggregation. The protein has a molecular weight of approximately 17,000. A method of isolating the protein from Ornithodoros moubata and using the protein to prevent or delay blood coagulation by blocking the stimulation of platelet aggregation by collagen is also described. The protein is useful in the prevention, prophylaxis, therapy and treatment of thrombotic diseases.Type: GrantFiled: August 16, 1993Date of Patent: August 23, 1994Assignee: Merck & Co., Inc.Inventors: Thomas M. Connolly, Paul M. Keller, Lloyd H. Waxman
-
Patent number: 5324715Abstract: A protein isolated from crude Haementeria officinalis extract which blocks stimulation of platelet aggregation by collagen. The protein has a molecular weight of approximately 16,000. A method of isolating the protein and using the protein to prevent or delay blood coagulation by blocking the stimulation of platelet aggregation by collagen is also described. The protein is useful in the prevention, prophylaxis, therapy and treatment of thrombotic diseases.Type: GrantFiled: April 7, 1993Date of Patent: June 28, 1994Assignee: Merck & Co., Inc.Inventors: Thomas M. Connolly, Paul M. Keller
-
Patent number: 5306635Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.Type: GrantFiled: June 9, 1992Date of Patent: April 26, 1994Assignee: Merck & Co., Inc.Inventors: Paul M. Keller, Mark W. Riemen, Ronald W. Ellis, Andrew J. Davison, Robert S. Lowe
-
Patent number: 4952674Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.Type: GrantFiled: May 2, 1986Date of Patent: August 28, 1990Assignee: Merck & Co., Inc.Inventors: Paul M. Keller, Ronald W. Ellis, Robert S. Lowe, Mark W. Riemen, Andrew J. Davison
-
Patent number: 4812559Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human convalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.Type: GrantFiled: March 23, 1987Date of Patent: March 14, 1989Assignee: Merck & Co., Inc.Inventors: Ronald W. Ellis, Paul M. Keller, Robert S. Lowe, Andrew J. Davison
-
Patent number: 4769239Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified through DNA sequence analysis. Fragments of the DNA have been cloned into a vector which, when placed into a host organism, expresses proteins which react with human convalescent zoster sera and with monoclonal antibodies which neutralize viral infectivity. These proteins are useful for preparation of a vaccine for VZV.Type: GrantFiled: August 21, 1984Date of Patent: September 6, 1988Assignee: Merck & Co., Inc.Inventors: Ronald W. Ellis, Paul M. Keller
-
Patent number: 4686101Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human canvalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.Type: GrantFiled: August 2, 1985Date of Patent: August 11, 1987Assignee: Merck & Co., Inc.Inventors: Ronald W. Ellis, Robert S. Lowe, Paul M. Keller, Andrew J. Davison